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Guest Editorial
Blood Coagulation and Heart Disease
YOK-LAM KWONG
From Division of Haematology / Oncology and Bone Marrow Transplantation, Department of Medicine, University
of Hong Kong, Queen Mary Hospital

Blood coagulation is a sword with two edges.
On the one hand, it is quickly activated after trauma
to blood vessels and thereby prevents excessive blood
loss. On the other hand, the inappropriate activation
of coagulation leads to blockage of blood vessels,
manifesting clinically as arterial and venous
thrombosis. The growing recognition that thrombosis
is important in the pathogenesis of a variety of
diseases has led to the search for effective and safe
anti-thrombotic agents.1
Platelet activation is one of the first steps in
the initiation of blood coagulation. Activated platelets
form a platelet plug that not only leads to the
activation of coagulation factors, but also provides
surface phospholipid that participates in coagulation.
The inhibition of platelet activation is an effective
way of preventing or abating the acute coronary
syndrome. This has been the topic of a previous
editorial.2
The activation of coagulation factors is another
important step leading to thrombosis. Although
traditionally coagulation is seen to comprise two
distinct pathways, the "intrinsic" and "extrinsic"
pathways, it is now recognised that these are artificial
and only observed ex vivo. The actual coagulation
mechanism in vivo is likely to be more complex, and
consists of a series of feedback loops, with the
interaction of tissue factor and factor VII being the
first initiating event.
Once the coagulation is initiated, the molecule
thrombin, which cleaves fibrinogen into clottable
fibrin, plays a central role in the further propagation
of the clot. Thrombin is a pivotal molecule in several
important steps in coagulation. Firstly, thrombin is
responsible for its own formation via a positive
feedback mechanism. Secondly, thrombin is the most
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potent platelet activator known. Thirdly, thrombin
activates three of the four cofactors (factors V and
VIII, thrombomodulin, but not tissue factor) that are
important in the coagulation pathway. Finally,
thrombin activates factor XIII which increases the
strength of fibrin, making it less susceptible to
thrombolysis.
Inhibition of thrombin has therefore become
one of the most recent pharmacological approaches
to the control of thrombosis. Indirect inhibitors of
thrombins, including unfractionated heparin and
fractionated low molecular weight heparin, act by
binding to anti-thrombin III to enhance its action.
Direct thrombin inhibitors, however, work
independently of anti-thrombin III. They effectively
inhibit fibrin-bound thrombin and thrombin-induced
platelet activation. Furthermore, they do not
appreciably bind to plasma proteins and do not cause
immune mediated thrombocytopenia.3 A comparison
of these thrombin inhibitors is given in table 1.
Chen and Lau,4 in a review article in this issue
of the Journal, have summarised succinctly the recent
clinical data on the use of various anti-thrombins in
acute coronary syndromes. The use of these various
agents is guided by several important considerations,
viz., efficacy, risk of bleeding, side effects, easy of
administration, and cost. Clinicians have a longer
experience with the use of indirect thrombin
inhibitors, and with the advent of fractionated low
molecular weight heparin many of the problems
associated with unfractionated heparin have been
overcome. The direct thrombin inhibitors have a
stable anticoagulant activity and a uniform
pharmacological composition, but no effective
antidote. It seems likely that, theoretical aspects
aside, the ultimate choice of what anti-thrombins to
use in coronary heart disease will depend on large
clinical trials that address the efficacy and safety of
these agents. More to explore will be how these drugs
may be used in combination with agents that inhibit
platelet activation and function to maximise anticoagulation.
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Table 1.

Comparison of the thrombin inhibitors

Indirect thrombin inhibitors
Unfractionated heparin
Low molecular weight heparin

Direct thrombin inhibitors

inhibits thrombin more than IXa and
XIa. Anti-thrombin III dependent.
Not active on clot-bound thrombin

inhibits factor Xa and thrombin
equally. Anti-thrombin III
dependent. Not active on clotbound thrombin

inhibit only thrombin
Anti-thrombin III independent.
Active on clot-bound thrombin

neutralised by heparinase and plasma
proteins

neutralised by heparinase

not neutralised by heparinase or
plasma proteins

may induced immune mediated
thrombocytopenia

induces thrombocytopenia
rarely

do not induce thrombocytopenia

subcutaneous injection :
bioavailability only 30%

subcutaneous injection :
bioavailability 90%

subcutaneous injection :
bioavailability 90%

increases vascular permeability
permeability

does not increase vascular
permeability

do not increase vascular

not immunogenic

not immunogenic

may be immunogenic
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